Literature DB >> 9079663

The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR.

S R Brand1, R Kobayashi, M B Mathews.   

Abstract

We demonstrate that the interferon-induced, double-stranded (ds) RNA-activated kinase, PKR, is able to bind to and phosphorylate the human immunodeficiency virus type 1 (HIV-1) trans-activating protein, Tat. Furthermore, Tat can inhibit the activation and activity of the kinase. Phosphorylation of Tat by PKR is dependent on the prior activation of PKR by dsRNA and occurs on serine and threonine residues adjacent to the basic region important for TAR RNA binding and Tat function. Activated PKR efficiently phosphorylates both the two-exon form of Tat (Tat-86) and the single exon form (Tat-72). Mutagenesis indicates that the interaction between PKR and Tat requires the RNA-binding region of Tat. Tat competes with eukaryotic initiation factor 2, a well-characterized substrate of PKR, for phosphorylation by activated PKR. Tat also inhibits the autophosphorylation of PKR by dsRNA. This biochemical evidence of an intimate relationship between Tat, an important regulator of HIV transcription, and PKR, a pleiotropic cellular regulator, may provide insights into HIV-1 pathogenesis and, more generally, virus/host interactions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9079663     DOI: 10.1074/jbc.272.13.8388

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

Review 1.  Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor.

Authors:  R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR.

Authors:  F Demarchi; M I Gutierrez; M Giacca
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 3.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

4.  The 3'-untranslated regions of cytoskeletal muscle mRNAs inhibit translation by activating the double-stranded RNA-dependent protein kinase PKR.

Authors:  Jean M Nussbaum; Shobha Gunnery; Michael B Mathews
Journal:  Nucleic Acids Res       Date:  2002-03-01       Impact factor: 16.971

5.  The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain.

Authors:  Kevin A Cassady; Martin Gross
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation.

Authors:  S Nanduri; B W Carpick; Y Yang; B R Williams; J Qin
Journal:  EMBO J       Date:  1998-09-15       Impact factor: 11.598

7.  The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR.

Authors:  Viraj R Sanghvi; Laura F Steel
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

8.  Double-stranded RNA-independent dimerization of interferon-induced protein kinase PKR and inhibition of dimerization by the cellular P58IPK inhibitor.

Authors:  S L Tan; M J Gale; M G Katze
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

9.  Potentiation of human immunodeficiency virus type 1 Tat by human cellular proteins.

Authors:  M E Greenberg; D A Ostapenko; M B Mathews
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

10.  ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication.

Authors:  Guerline Clerzius; Jean-François Gélinas; Aïcha Daher; Marion Bonnet; Eliane F Meurs; Anne Gatignol
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.